VTGN — Vistagen Therapeutics Share Price
0.000.00%
Last trade - 00:00- $85.70m
- $5.22m
- $0.49m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.22 | ||
| Price to Tang. Book | 1.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 176.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -78.03% | ||
| Return on Equity | -55.68% | ||
| Operating Margin | -11517.08% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.09 | 1.11 | -0.23 | 1.06 | 0.49 | 0.59 | 4.49 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
Directors
- Jon Saxe NEC (85)
- H. Ralph Snodgrass PRE (71)
- Shawn Singh CEO (58)
- Jerrold Dotson CFO (68)
- Mark Ginski SVP (49)
- Ann Cunningham OTH (53)
- Mark Smith OTH (65)
- Joanne Curley IND (53)
- Margaret Fitzpatrick IND (55)
- Jerry Gin IND (78)
- Mary Rotunno IND (61)
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- October 6th, 2005
- Public Since
- October 18th, 2010
- No. of Shareholders
- 357
- No. of Employees
- 56
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 29,859,961
- Address
- 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.vistagen.com/
- Phone
- +1 6505773600
- Contact
- Mark Mcpartland
- Auditors
- KPMG LLP
Upcoming Events for VTGN
Vistagen Therapeutics Inc Annual Shareholders Meeting
Q2 2026 Vistagen Therapeutics Inc Earnings Release
Similar to VTGN
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Vistagen Therapeutics share price?
As of Today at 06:01 UTC, shares in Vistagen Therapeutics are trading at $2.87. This share price information is delayed by 15 minutes.
How has the Vistagen Therapeutics share price performed this year?
Shares in Vistagen Therapeutics last closed at $2.87 and the price had moved by -16.33% over the past 365 days. In terms of relative price strength the Vistagen Therapeutics share price has underperformed the S&P500 Index by -28.11% over the past year.
What are the analyst and broker recommendations for Vistagen Therapeutics?
The overall consensus recommendation for Vistagen Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vistagen Therapeutics dividend yield?
Vistagen Therapeutics does not currently pay a dividend.
Does Vistagen Therapeutics pay a dividend?
Vistagen Therapeutics does not currently pay a dividend.
When does Vistagen Therapeutics next pay dividends?
Vistagen Therapeutics does not currently pay a dividend.
How do I buy Vistagen Therapeutics shares?
To buy shares in Vistagen Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vistagen Therapeutics?
As of the previous close price of $2.87, shares in Vistagen Therapeutics had a market capitalisation of $85.70m.
Where are Vistagen Therapeutics shares listed?
Here are the trading details for Vistagen Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VTGN
What kind of share is Vistagen Therapeutics?
Based on an overall assessment of its quality, value and momentum Vistagen Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vistagen Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Vistagen Therapeutics is $13.00. That is 352.96% above the last closing price of $2.87.
Analysts covering Vistagen Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.59 for the next financial year.
Find out moreWhat is the trend in the Vistagen Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vistagen Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -6.09%.
As of the last closing price of $2.87, shares in Vistagen Therapeutics were trading +9.79% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vistagen Therapeutics PE Ratio?
The Vistagen Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vistagen Therapeutics?
Vistagen Therapeutics' management team is headed by:
- Jon Saxe - NEC
- H. Ralph Snodgrass - PRE
- Shawn Singh - CEO
- Jerrold Dotson - CFO
- Mark Ginski - SVP
- Ann Cunningham - OTH
- Mark Smith - OTH
- Joanne Curley - IND
- Margaret Fitzpatrick - IND
- Jerry Gin - IND
- Mary Rotunno - IND